These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 16462182

  • 1. Treatment of non-small-cell lung cancer and pharmacogenomics: where we are and where we are going.
    Rosell R, Cuello M, Cecere F, Santarpia M, Reguart N, Felip E, Taron M.
    Curr Opin Oncol; 2006 Mar; 18(2):135-43. PubMed ID: 16462182
    [Abstract] [Full Text] [Related]

  • 2. The place of targeted therapies in the management of non-small cell bronchial carcinoma. Molecular markers as predictors of tumor response and survival in lung cancer.
    Rosell R, Moran T, Fernanda Salazar M, Mendez P, De Aguirre I, Ramirez JL, Isla D, Cobo M, Camps C, Lopez-Vivanco G, Alberola V, Taron M.
    Rev Mal Respir; 2006 Nov; 23(5 Pt 3):16S131-16S136. PubMed ID: 17268350
    [Abstract] [Full Text] [Related]

  • 3. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A, Sørensen JB.
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [Abstract] [Full Text] [Related]

  • 4. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
    Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Viñolas N, Paz-Ares L, Lopez-Vivanco G, Muñoz MA, Felip E, Alberola V, Camps C, Domine M, Sanchez JJ, Sanchez-Ronco M, Danenberg K, Taron M, Gandara D, Rosell R.
    J Clin Oncol; 2007 Jul 01; 25(19):2747-54. PubMed ID: 17602080
    [Abstract] [Full Text] [Related]

  • 5. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer.
    Olaussen KA, Mountzios G, Soria JC.
    Curr Opin Pulm Med; 2007 Jul 01; 13(4):284-9. PubMed ID: 17534174
    [Abstract] [Full Text] [Related]

  • 6. Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response.
    Felip E, Rosell R.
    Expert Rev Mol Diagn; 2007 May 01; 7(3):261-8. PubMed ID: 17489733
    [Abstract] [Full Text] [Related]

  • 7. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, Sung SW, Kim JH.
    Lung Cancer; 2008 Jun 01; 60(3):401-7. PubMed ID: 18036700
    [Abstract] [Full Text] [Related]

  • 8. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
    Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC.
    Clin Cancer Res; 2004 Aug 01; 10(15):4939-43. PubMed ID: 15297394
    [Abstract] [Full Text] [Related]

  • 9. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
    Simon G, Sharma A, Li X, Hazelton T, Walsh F, Williams C, Chiappori A, Haura E, Tanvetyanon T, Antonia S, Cantor A, Bepler G.
    J Clin Oncol; 2007 Jul 01; 25(19):2741-6. PubMed ID: 17602079
    [Abstract] [Full Text] [Related]

  • 10. Synchronous alterations of Wnt and epidermal growth factor receptor signaling pathways through aberrant methylation and mutation in non small cell lung cancer.
    Suzuki M, Shigematsu H, Nakajima T, Kubo R, Motohashi S, Sekine Y, Shibuya K, Iizasa T, Hiroshima K, Nakatani Y, Gazdar AF, Fujisawa T.
    Clin Cancer Res; 2007 Oct 15; 13(20):6087-92. PubMed ID: 17947472
    [Abstract] [Full Text] [Related]

  • 11. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X, Li F, Sun N, Shukui Q, Baoan C, Jifeng F, Lu C, Zuhong L, Hongyan C, YuanDong C, Jiazhong J, Yingfeng Z.
    Lung Cancer; 2009 Aug 15; 65(2):230-6. PubMed ID: 19157633
    [Abstract] [Full Text] [Related]

  • 12. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T, Liu G, Tsao MS.
    Oncogene; 2009 Aug 15; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [Abstract] [Full Text] [Related]

  • 13. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 15; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 14. Characterization of functional excision repair cross-complementation group 1 variants and their association with lung cancer risk and prognosis.
    Yu D, Zhang X, Liu J, Yuan P, Tan W, Guo Y, Sun T, Zhao D, Yang M, Liu J, Xu B, Lin D.
    Clin Cancer Res; 2008 May 01; 14(9):2878-86. PubMed ID: 18451256
    [Abstract] [Full Text] [Related]

  • 15. Excision repair cross complementation group 1 polymorphisms predict overall survival after platinum-based chemotherapy for completely resected non-small-cell lung cancer.
    Okuda K, Sasaki H, Hikosaka Y, Kawano O, Yukiue H, Yano M, Fujii Y.
    J Surg Res; 2011 Jun 15; 168(2):206-12. PubMed ID: 20070981
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.